For research use only
| Cat No. | ABC-TC0587 |
| Product Type | Human Lung Cancer Cell Lines |
| Cell Type | Epithelial-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Product Code | LK 2; LK2 |
Explore the LK-2 cell line, derived from a 74-year-old male with lung squamous cell carcinoma, known for its epithelial characteristics.
LK-2 cells are a human lung squamous cell carcinoma line derived from a primary tumor. These adherent cells display polygonal, epithelial-like morphology and sustain continuous in vitro passage. LK-2 cells express cytokeratins and exhibit markers of squamous differentiation. They harbor genetic alterations common to lung squamous carcinoma, including TP53 mutations, contributing to their tumorigenic and invasive phenotype. These cells demonstrate robust proliferative and invasive capabilities, making them a valuable model for investigating lung squamous cell carcinoma biology, tumor progression, and therapeutic responses. The LK2 cell lines are widely used to explore mechanisms underlying carcinogenesis, drug resistance, and to evaluate chemotherapeutic and targeted treatments in lung cancer research.
| Product Code | LK 2; LK2 |
| Species | Human |
| Cat.No | ABC-TC0587 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
Squamous cell carcinoma (SCC) research advances cancer biology by investigating molecular mechanisms, genetic mutations, signaling pathways, and immune responses underlying its pathogenesis. LK-2 cells enable biomarker identification for diagnostic/prognostic tools to improve early intervention and guides therapeutic approaches through targeted drug discovery that selectively exploits cancer cell vulnerabilities. This work facilitates precision medicine by correlating genetic alterations with treatments and drives immunotherapy development through tumor microenvironment analysis. SCC studies utilizing LK-2 cells further inform clinical trial designs for novel therapies while enhancing public health education on risk factors and prevention strategies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
